Carmustine and streptozocin in refractory melanoma: An attempt at modulation of O6-alkylguanine-DNA-alkyltransferase

Clinical Cancer Research

Volumn 2, Issue 7, 1996, Pages 1129-1134

  Smith, David C ^a,b,d   Gerson, Stanton L ^c   Liu, Lili ^c   Donnelly, Sandra ^b   Day, Roger ^b   Trump, Donald L ^a,b   Kirkwood, John M ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; CARMUSTINE; STREPTOZOCIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CELL KILLING; CLINICAL ARTICLE; CLINICAL TRIAL; COVALENT BOND; DNA STRAND; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME MODIFICATION; FEMALE; HUMAN; INTERMEDIATE FILAMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION; MALE; MELANOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; DACARBAZINE; FEMALE; GLUTATHIONE; HUMANS; MALE; MELANOMA; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; STREPTOZOCIN;

EID: 0029937517     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Colvin, M., and Chabner, B. A. Alkylating agents. In: B. A. Chabner and J. M. Collins (eds.), Cancer Chemotherapy Principles and Practice, pp. 276-313, Philadelphia: J. B. Lippincott Co., 1990.
2. Mitchell, E. P., and Schein, P. S. Nitrosoureas. In: M. C. Perry (ed.), The Chemotherapy Source Book, pp. 384-397: Baltimore, MD: Williams & Wilkins, 1992.
3. 6-alkyl guanine alkyltransferase in cancer chemotherapy. Cancer Treat. Rev., 15: 279-292, 1988.
4. 6-Alkylguanine-DNA alkyltransferase. Regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res., 50: 6119-6129, 1990.
5. 6-methylguanine in DNA to inactivation by alklylating agents including chloroethylnitrosoureas. Cancer Res., 44: 2467-2474, 1984.
6. Kohn, K. W. Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res., 37: 1450-1454, 1977.
7. 6-alkylguanine DNA alkyltransferase becomes covalently bound to DNA containing 1,3-bis(2-chloroethyl)-1-nitrosourea-induced precursors of interstrand cross-links. Biochem. Biophys. Res. Commun., 142: 341-347, 1987.
8. 6-methylguanine-DNA methyltransferase gene MGMT in human normal and tumor tissues. J. Natl. Cancer Inst., 84: 337-340, 1992.
9. Bennet, R., and Pegg, A. E. Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res., 41: 2786-2790, 1981.
10. Futscher, B. W., Micetich, K. C , Barnes, D. M., Fisher, R. I., and Erickson, L. C. Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells. Cancer Commun., I: 65-73, 1989.
11. 6-methylguanine DNA methyltransferase activity and mRNA levels in HT-29 cells in vitro. Cancer Res., 51. 1581-1585, 1991.
12. 6-alkylguanine-DNA alkyltransferase by streptozotocin in vivo. Cancer Res., 49: 3134-3138, 1989.
13. Micetich, K. C., Futscher, B., Koch, D., Fisher, R I., and Ericksen, L. C. Phase I study of streptozotocin and carmustine-sequenced administration in patients with advanced cancer. J. Natl. Cancer Inst., 84: 256-260, 1992.
14. 6-AGAT-mediated carmustine (BCNU) resistance using streptozotocin: a Phase I trial. Cancer Res., 52: 2456-2459, 1992.
15. 6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers. J. Clin. Oncol., 13: 2301-2308, 1995.
16. Bellet, R. E., Mastrangelo, M. J., Laucius, J. F., and Bodurtha, A. J. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. Cancer Treat. Rep., 60: 595-600, 1976.
17. 6-alkylguanine -DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis (Lond.). 7: 745-749, 1986.
18. Simon, R. Optimal two-stage designs for Phase II clinical trials. Controlled Clin. Trials, 10: 1-10, 1989.
19. Mastrangelo, M. J., Bellet, R. E., Kane, M. J., and Berd, D. Chemotherapy of melanoma. In: M. C. Perry (ed.), Chemotherapy Source Book, pp., 886-907, Baltimore, MD. Williams & Wilkins, 1995
20. Carter, R. D., Krementz, E. T., Hill, G. J., II, Metter, G. E., Fletcher, W. S., Golomb, F. M., Grage, T. B., Minton, J. P., and Sparks, F. C. DTIC (NSC-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). Cancer Treat. Rep., 60: 601-609, 1976
21. Ahmann, D. L. Nitrosoureas in the management of disseminated malignant melanoma. Cancer Treat Rep., 60: 747-751, 1976.
22. Costanzi, J. J. DTIC (NSC-45388) studies in the Southwest Oncol-ogy Group. Cancer Treat. Rep., 60: 189-192, 1976.
23. Meer, L., Janzer, R C., Kleihues, P., and Kolar, G F. In vivo metabolism and reaction with DNA of the cytostatic agent, 5-(3, 3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). Biochem. Pharmacol., 35: 3243-3247, 1986.
24. Maynard, K., Parsons, P. G., Cerny, T., and Margison, G. P. Relationships among cell survival, O6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adenovirus 5 and herpes simplex virus type 1 in human melanoma cell lines. Cancer Res., 49: 4813-4817, 1989
25. 6-Alkylguanine-DNA alkyltransferase activity in human malignant melanoma. J. Dermatol. Sci., 4: 6-10, 1992.
26. 6-Methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumors. Br. J. Cancer, 71: 37-39, 1995.
27. Avril, M. F., Bonneterre, J., Delaunay, M., Grosshans, E., Fumoleua, P., Israel, L., Bugat, R., Namer, M., Cupissol, D., Kerbrat, P., Montcuquet, P , Arcaute, V., and Bizzari, J-P. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma Experience of the French Study Group. Cancer Chemother. Pharmacol., 27. 81-84, 1990.
28. Aamdal, S., Gerard, B., Bohman, T., and D'Incalci, M. Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma-an effective combination with unexpected toxicity. Eur. J. Cancer, 28: 447-450, 1992.
29. Gerard, B., Aamdal, S., Lee, S. M , Leyvraz, S., Lucas, C., D'Incalci, M., and Bizzari, J. P. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents - dacarbazine and fotemustine - in patients with melanoma. Eur. J. Cancer, 29A: 711-719, 1993.
30. Aronin, P. A , Mahaley, M. S., Jr., Rudnick, S. A., Dudka, L., Donohue, J F., Selker, R. G., and Moore, P. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N. Engl. J. Med., 303: 183-188, 1980.
31. Twohig, K. J., and Matthay, R. A. Pulmonary effects of cytotoxic agents other than bleomycin. Clin. Chest Med., 11: 31-54, 1990.
32. Weiss, R. B., Poster, D S., and Penta, J. S. The nitrosoureas and pulmonary toxicity. Cancer Treat. Rev., 8: 111-125, 1981.
33. Slonim, A. E., Fletcher, T., Burke, V., and Burr, I. M. Effect of streptozotocin on red-blood-cell-reduced glutathione. modification by glucose, nicotinamide, and epinephrine. Diabetes, 25. 216-222, 1976.
34. Agius, C., and Gidari, A. S. Effect of streptozotocin on the glutathione S-transferases of mouse liver cytosol. Biochem. Pharmacol., 34: 811-819, 1985.
35. Michels, S. D., McKenna, R. W., Arthur, D. C., and Brunning, R. D. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood, 65: 1364-1372, 1985.
36. Boice, J. D., Jr., Greene, M. H., Killen, J Y., Jr., Ellenberg, S. S., Keehn, R. J., McFadden, E., Chen, T T., and Fraumeni, J. F., Jr. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N. Engl. J. Med., 309: 1079-1084, 1983.
37. 6-Alkylguanine-DNA alkyltransferase activity in human myeloid cells. J. Clin Invest., 76: 2106-2114, 1985.
38. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. Sci. USA, 87: 5368-5372, 1990.
39. 6-alkylguanine-DNA alkyltransferase. J. Cancer Res Clin. Oncol, 121: 225-229, 1995.
40. 6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue. Cancer Chemother. Pharmacol., 31: 240-246, 1992.
41. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br. J. Cancer, 69: 452-456, 1994.